Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025:3:IMAG.a.83.
doi: 10.1162/imag.a.83. Epub 2025 Jul 16.

Spatial and Temporal Progression of Neurodegeneration in Confirmed and Suspected TDP-43 Type C Pathology

Affiliations

Spatial and Temporal Progression of Neurodegeneration in Confirmed and Suspected TDP-43 Type C Pathology

Jane Stocks et al. Imaging Neurosci (Camb). 2025.

Abstract

The delineation of disease progression in neurodegenerative entities offers neurobiological insights into pathophysiology as well as practical information on natural progression that can be used to gauge the benefits of treatment. In AD, FTLD-tau and FTLD-TDP types A and B such advances have been achieved based on the investigation of presymptomatic mutation carriers. In the absence of dominant mutations, this approach is not feasible in FTLD-TDP type C (TDP-C). Considering the subtlety of the initial symptoms, it is almost certain that the disease had been progressing for years before the first investigations are obtained. We addressed this limitation through an indirect approach based on the fact that neurodegeneration in TDP-C can be asymmetric for 5-6 years after symptom onset. In time, the contralateral hemisphere starts to show the onset of atrophy, the spread of which mirrors the pattern in the affected hemisphere. The unaffected hemisphere therefore offers an opportunity for capturing the very first emergence of atrophy. To that end, we traced the onset and progression of neurodegeneration in TDP-C by analyzing the right hemisphere longitudinally in cases of asymmetric left anterior temporal atrophy. In these cases, TDP-C was either confirmed at autopsy or suspected based on the clinical features and anatomy of atrophy. Structural MRIs were processed using voxel-based morphometry and parcellated into cortical and subcortical regions. W-scores were computed to identify volume loss relative to age-matched controls. Linear mixed-effects models assessed disease progression across regions of interest (ROIs). Results of our analyses reveal that atrophy in TDP-C follows a stereotyped progression within the right hemisphere, beginning in the ventromedial anterior temporal lobe and extending posteriorly and laterally over time. Early atrophy was most prominent in the medial temporal pole (planum polare), perirhinal cortex, entorhinal cortex, and anterior fusiform cortex, with subcortical involvement initially limited to the amygdala. Voxelwise and ROI-based analyses confirmed that cortical atrophy preceded and exceeded amygdala atrophy in most cases, suggesting greater neocortical vulnerability. Longitudinal linear mixed-effects models identified the greatest volume loss in medial temporal ROIs and the amygdala, following a consistent anterior-to-posterior gradient over time. These findings reconstruct the spatial and temporal progression of TDP-C pathology using the initially unaffected hemisphere as a proxy for early disease stages. The stereotyped trajectory of atrophy aligns with neuropathological patterns and offers critical insights into disease progression, aiding therapeutic evaluation.

Keywords: MRI; Neurodegeneration; TDP-43; atrophy; longitudinal; primary progressive aphasia.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors declare no competing interests.

Figures

Fig. 1.
Fig. 1.
Percentage of Participants with Brain Volume W-Scores Below -1.5 in Right Hemisphere Regions of Interest (ROIs) at Visits A, B, and C This figure illustrates the percentage of participants with brain volume W-scores below -1.5, based on comparison to normal controls, in 180 right hemisphere ROIs derived from the Glasser et al. (2016) HCP-MMP atlas for visits A, B, and C. Subcortical regions are parcellated according to the Tian et al. (2020) atlas; labels are intended to aid interpretability and do not reflect definitive subregional boundaries. Visualizations are thresholded at 25%, displaying ROIs where 25% or more participants fall below the W-score threshold across the three visits. PRC = perirhinal cortex, EC = entorhinal cortex, aFG = anterior fusiform gyrus, PHA = parahippocampal area, PreS = presubiculum, pTG/VWFA = posterior temporal gyrus/visual word form area, midFG = middle fusiform gyrus, midMTG/ITG = middle and inferior temporal gyri, aMTG/ITG = anterior middle and inferior temporal gyri, pSTG/STS = posterior superior temporal gyrus and superior temporal sulcus, TPR = temporal pole region, Pir = piriform cortex, Ins = insula, and IFGorb = orbital portion of the inferior frontal gyrus. l/m-AMY = lateral and medial amygdala.
Fig. 2.
Fig. 2.
High Threshold Percentage of Participants with Brain Volume W-Scores Below -1.5 Visualized Voxelwise in the Right Hemisphere at Visit A. This figure presents voxelwise visualizations of the percentage of participants with brain volume W-scores below -1.5, in the right hemisphere, for visit A only. Data are thresholded at 80%, with axial slices showing areas where 80% or more participants fall below the W-score threshold. Figure labels based on Mai et al. (2015); labels are intended to aid interpretability and do not reflect definitive subregional boundaries. Ppo = Planum polare, ITP = Inferior temporopolar region, STG = Superior temporal gyrus, MTG = Middle temporal gyrus, Pir = Piriform Cortex, Ent = Entorhinal cortex, PRC = perirhinal cortex, AMY = amygdala, FuG = fusiform gyrus.
Fig. 3.
Fig. 3.
Percentage of Participants with Brain Volume W-Scores Below -1.5 Visualized Voxelwise in the Right Hemisphere at Visits A, B, and C. This figure presents voxelwise visualizations of the percentage of participants with brain volume W-scores below -1.5, compared to normal controls, in the right hemisphere, for visits A, B, and C. Data are thresholded at 25%, with axial slices showing areas where 25% or more participants fall below the W-score threshold. The voxelwise analysis provides detailed insight into specific regions of interest across the right hemisphere. Figure labels based on Mai et al. (2015); labels are intended to aid interpretability and do not reflect definitive subregional boundaries. Ppo = Planum polare, ITP = Inferior temporopolar region, STG = Superior temporal gyrus, MTG = Middle temporal gyrus, ITG = Inferior temporal gyrus, Pir = Piriform Cortex, Ent = Entorhinal cortex, PAM = periamygdaloid complex, AMY = amygdala, FuG = fusiform gyrus, HIH = hippocampal head, DG = dentate gyrus.
Fig. 4.
Fig. 4.
Effects of Years Since Symptom Onset on Brain Volume. This figure displays the results of linear mixed-effects models examining the effect of disease duration on brain volume across 180 right-hemisphere regions of interest (ROIs) from the Glasser et al. (2016) HCP-MMP atlas and 16 subcortical ROIs from Tian et al. (2020); labels are intended to aid interpretability and do not reflect definitive subregional boundaries. Lighter yellow values correspond to faster rates of volume loss per year since symptom onset. The colorbar is thresholded to display only ROIs exceeding a stringent FDR-corrected significance level. PRC = perirhinal cortex, EC = entorhinal cortex, aFG = anterior fusiform gyrus, PHA = parahippocampal area, PreS = presubiculum, pTG/VWFA = posterior temporal gyrus/visual word form area, midFG = middle fusiform gyrus, midMTG/ITG = middle and inferior temporal gyri, aMTG/ITG = anterior middle and inferior temporal gyri, pSTG/STS = posterior superior temporal gyrus and superior temporal sulcus, TPR = temporal pole region, Pir = piriform cortex, Ins = insula, and IFGorb = orbital portion of the inferior frontal gyrus.

Similar articles

  • Short-Term Memory Impairment.
    Cascella M, Al Khalili Y. Cascella M, et al. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31424720 Free Books & Documents.
  • Medial temporal lobe Tau-Neurodegeneration mismatch from MRI and plasma biomarkers identifies vulnerable and resilient phenotypes with AD.
    Lyu X, Mundada NS, Brown CA, Sadeghpour N, McGrew E, Xie L, Li Y, Wuestefeld A, Duong MT, Cook P, Gee J, Nasrallah IM, Chen-Plotkin AS, Shaw LM, Mechanic-Hamilton D, Wisse LEM, Yushkevich PA, Das SR, Wolk DA; Alzheimer’s Disease Neuroimaging Initiative. Lyu X, et al. medRxiv [Preprint]. 2025 Aug 19:2025.08.17.25333859. doi: 10.1101/2025.08.17.25333859. medRxiv. 2025. PMID: 40894164 Free PMC article. Preprint.
  • Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum.
    Buehner BJ, Morcillo-Nieto AO, Zsadanyi SE, Rozalem Aranha M, Arriola-Infante JE, Vaqué-Alcázar L, Arranz J, Rodríguez-Baz Í, Maure Blesa L, Videla L, Barroeta I, Del Hoyo Soriano L, Benejam B, Fernández S, Sanjuan Hernandez A, Bargalló N, González-Ortiz S, Giménez S, de Flores R, Yushkevich PA, Alcolea D, Belbin O, Lleó A, Carmona-Iragui M, Fortea J, Bejanin A. Buehner BJ, et al. Brain. 2025 Jul 7;148(7):2509-2521. doi: 10.1093/brain/awaf133. Brain. 2025. PMID: 40243675
  • Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
    Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Domen J, Tans A, Janssens S, Wickramasinghe D, Lannoy V, Horn SRA, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Struyf T, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
  • The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C, Schatzberg AF. DeBattista C, et al. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.

References

    1. Ashburner, J., & Friston, K. J. (2005). Unified segmentation. Neuroimage, 26(3), 839–851. 10.1016/j.neuroimage.2005.02.018 - DOI - PubMed
    1. Barbas, H. (2015). General cortical and special prefrontal connections: Principles from structure to function. Annual Review of Neuroscience, 38(1), 269–289. 10.1146/annurev-neuro-071714-033936 - DOI - PubMed
    1. Bocchetta, M., Iglesias Espinosa, M. D. M., Lashley, T.,Warren, J. D., & Rohrer, J. D. (2020). In vivo staging of frontotemporal lobar degeneration TDP-43 type C pathology. Alzheimer’s Research & Therapy, 12, 1–8. 10.1186/s13195-020-00600-x - DOI - PMC - PubMed
    1. Bonner, M. F., & Price, A. R. (2013). Where is the anterior temporal lobe and what does it do? Journal of Neuroscience, 33(10), 4213–4215. 10.1523/jneurosci.0041-13.2013 - DOI - PMC - PubMed
    1. Borghesani, V., Battistella, G., Mandelli, M., Welch, A., Weis, E., Younes, K., Neuhaus, J., Grinberg, L., Seeley, W., & Spina, S. (2020). Regional and hemispheric susceptibility of the temporal lobe to FTLD-TDP type C pathology. NeuroImage: Clinical, 28, 102369. 10.1016/j.nicl.2020.102369 - DOI - PMC - PubMed

LinkOut - more resources